Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase I/II Study of HDM201 Added to Chemotherapy in AML
NCT03760445Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of siremadlin in acute myeloid leukemia (AML), sponsored by Novartis. Planned start Nov 2019; status: withdrawn.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03760445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760445.